(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
When a sperm whale gives birth, the mother gets help from her friends - 2A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- 3Why the Houthis waited until now to strike
- 4Banks for High Fixed Store Rates: Augment Your Investment funds
- 5Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- America's Confided in Fridge in 2024
- Blue Origin safely launches wheelchair user to space and back
- NASA's giant moon rocket, in photos
- Different Film Classification: What's Your Go-To for Amusement
- CVS forecasts 2026 profit above estimates on strong performance
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- Consumer outlook on UK economy falls to two-year low
- How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
